We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

New Cell Therapy Offers Potential Treatment Option for Patients with Chronic Heart Failure

By HospiMedica International staff writers
Posted on 01 Mar 2023
Print article
Image: Physician-scientists have delivered a new first in heart failure treatment using cell therapy (Photo courtesy of The Texas Heart Institute)
Image: Physician-scientists have delivered a new first in heart failure treatment using cell therapy (Photo courtesy of The Texas Heart Institute)

Chronic heart failure is a progressively worsening condition caused by a decrease of the strength and pumping power of the heart. The current treatments are primarily aimed at reversing the negative effects of the complex neurohormonal pathways that are activated as a result of poor heart function. The activated pathways eventually contribute to the worsening of the disease and lead to more frequent hospitalizations. Despite advances in therapies targeting these pathways, mortality rates are still high. Now, the largest cell therapy trial to date in patients with chronic heart failure owing to low ejection fraction has shown that the therapy benefited patients by improving the heart’s pumping ability, as measured by ejection fraction, and reducing the risk of heart attack or stroke, especially in patients with high levels of inflammation. In addition, a strong signal was found in the reduction of cardiovascular death in patients treated with cells.

In the landmark clinical trial, physician-scientists at The Texas Heart Institute (Houston, TX, USA) showed that a special immunomodulatory cell type called MPC (mesenchymal precursor cells) developed by Mesoblast Inc. (Melbourne, Australia) has the potential to tackle one of the largest contributors to heart failure, inflammation. Participants in the trial were already making use of all available state-of-the-art heart failure drugs, which suggests that MPC cell therapy could work synergistically and add to the current medication in an effective way. The exceptional mode of action of MPC offers an alternative approach that has the possibility of significantly reducing the high mortality rate associated with heart failure.

The findings of beneficial long-term outcomes for patients with chronic heart failure due to lower ejection fraction and weakened pumping function are a major breakthrough in cell therapy for cardiovascular diseases. The results can help identify which heart failure patients with inflammation have the highest risk and likelihood to benefit from MPC therapy, and these findings will be further investigated in future studies. The groundbreaking trial has established the groundwork for potentially adding cell therapy to the treatment options available for heart failure.

“The results of DREAM-HF are an important step in understanding how cell therapy provides benefits in patients with chronic heart failure due to poor pump function,” said the study’s lead author, Dr. Emerson C. Perin, MD, Ph.D, Medical Director at The Texas Heart Institute. “The cells appear to work by reducing inflammation, increasing microvascular flow, and strengthening heart muscle. Locally, in the heart, the MPCs can protect cardiac muscle cells from dying and can improve blood flow and energetics. In large blood vessels throughout the body, the reduced inflammation resulting from the activation of MPCs may decrease plaque instability, which is what leads to heart attacks and strokes. The cells seem to have a systemic immune-modulatory and anti-inflammatory effect.”

Related Links:
The Texas Heart Institute
Mesoblast Inc. 

Gold Supplier
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
New
Portable X-Ray System
Delft Light
New
Bedside Transfusion Administration Software
BloodTrack Tx
New
Breathing Set
HAMILTON-BC8010

Print article
Radcal

Channels

Surgical Techniques

view channel
Image: New robust thermosensitive bioadhesives can improve surgical sealing (Photo courtesy of Pexels)

New Surgical Sealing Biomaterial Could Eliminate Standard Methods of Suturing and Stapling

For surgical wounds to be properly closed, the sealant material used must effectively seal on wet, slippery tissue surfaces that vary in shape and may involve tissue movement, such as an expanding lung,... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Business

view channel
Image: The demand for endometrial ablation devices is increasing due to rising prevalence of gynecological disorders (Photo courtesy of Pexels)

Global Endometrial Ablation Market Driven by Rising Prevalence of Gynecological Disorders

Gynecological disorders, such as menorrhagia, PCOD, abnormal vaginal bleeding, affect millions of women globally every year and are on the rise. Abnormal Uterine Bleeding (AUB) is the most common disorder... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.